ArticleSaudi journal of ophthalmology : official journal of the Saudi Ophthalmological Society
Indocyanine green-enhanced transpupillary thermotherapy in treatment of retinoblastoma: Experience in Indian eyes.
Article in Saudi journal of ophthalmology : official journal of the Saudi Ophthalmological Society. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe purpose of the study was to study the outcome of indocyanine green enhanced transpupillary thermotherapy (ICG-E TTT) in the treatment of reactivation of retinoblastoma (RB) showing poor response to standard TTT after 6 cycles of systemic chemotherapy in pigmented Indian eyes.
methodsAfter initial 6 cycles of standard-dose intravenous chemotherapy and focal consolidation with conventional TTT, ICG-E TTT was considered for reactivation of RB postchemotherapy when there was no response to 2 consecutive standard TTT or when there was minimal/inadequate response to 4 or more standard TTT. Examination under general anesthesia was done after 4 weeks, and process was repeated if required. Treatment success was described as achieving a treatment-free follow-up and decreasing the need for further chemotherapy.
resultsTen eyes of 8 babies (7 with bilateral RB) received ICG enhanced TTT. In 8 out 10 eyes, good regression was noted following ICG E TTT, for a mean of 2 times using a mean power of 350 mW. Seven out of 8 babies did not need re-starting systemic chemotherapy for recurrence. The mean treatment-free follow-up was 6.4 months.
conclusionUsing ICG-enhanced TTT, we achieved longer treatment-free follow-up and a decrease in the need for restarting systemic chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.